Arya Aminorroaya, MD/MPH
Postdoctoral AssociateAbout
Research
Publications
2024
Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction. European Heart Journal 2024, 45: ehae666.3190. DOI: 10.1093/eurheartj/ehae666.3190.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionImmune checkpoint inhibitorsGlobal longitudinal strainLeft ventricular systolic dysfunctionNon-Hodgkin's lymphomaCardiac dysfunctionAI-ECGNegative control analysesAssociated with higher incidenceVentricular systolic dysfunctionCohort of patientsRisk stratification strategiesCheckpoint inhibitorsTrastuzumab exposureSystolic dysfunctionRisk stratificationBreast cancerRisk biomarkersSecondary outcomesLongitudinal strainStratification strategiesTrastuzumabPatientsHigher incidenceAnthracyclinesArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screenComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelCorrelation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The GuidelinesĀ®-Resuscitation registry
Khera R, Aminorroaya A, Kennedy K, Chan P, Investigators A, Grossestreuer A, Moskowitz A, Ornato J, Churpek M, Starks M, Girotra S, Perman S. Correlation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The GuidelinesĀ®-Resuscitation registry. Resuscitation 2024, 202: 110322. PMID: 39029583, PMCID: PMC11390317, DOI: 10.1016/j.resuscitation.2024.110322.Peer-Reviewed Original ResearchRisk-standardized survival ratesIn-hospital cardiac arrestWeighted kappa coefficientResuscitation RegistryLong-term survivalSurvivors of in-hospital cardiac arrestHierarchical logistic regression modelsCardiac arrestIn-hospitalLogistic regression modelsLong-term outcomesSurvival dataKappa coefficientHospital performanceIn-hospital survivalMedicare filesMedicare beneficiariesYears of ageHospitalization ratesPost-discharge survivalHospital dischargeRate of survivalMedicareHospitalRegression modelsPerformance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study
Camargos A, Barreto S, Brant L, Ribeiro A, Dhingra L, Aminorroaya A, Bittencourt M, Figueiredo R, Khera R. Performance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study. Open Heart 2024, 11: e002762. PMID: 38862252, PMCID: PMC11168182, DOI: 10.1136/openhrt-2024-002762.Peer-Reviewed Original ResearchConceptsPooled Cohort EquationsELSA-BrasilRisk scoreCardiovascular diseaseCVD eventsCommunity-based cohort studyArea under the receiver operating characteristic curveCVD risk scoreELSA-Brasil studyIncident CVD eventsMiddle-income countriesAdjudicated CVD eventsCardiovascular disease riskCVD scoreCohort EquationsNational guidelinesRisk stratification scoresWhite womenAge/sex groupsCohort studyProspective cohortLMICsSex/race groupsHigher incomeRisk discriminationDevelopment and multinational validation of an algorithmic strategy for high Lp(a) screening
Aminorroaya A, Dhingra L, Oikonomou E, Saadatagah S, Thangaraj P, Vasisht Shankar S, Spatz E, Khera R. Development and multinational validation of an algorithmic strategy for high Lp(a) screening. Nature Cardiovascular Research 2024, 3: 558-566. PMID: 39195936, DOI: 10.1038/s44161-024-00469-1.Peer-Reviewed Original ResearchElectronic health recordsAssociated with premature atherosclerotic cardiovascular diseaseElevated Lp(aHealth recordsUK BiobankPremature atherosclerotic cardiovascular diseaseMachine learning modelsAtherosclerotic cardiovascular diseaseCohort studyReal-world settingsTargeted screeningCardiovascular diseaseLearning modelsNovel targeted therapeuticsAlgorithmic strategiesCohortProbability thresholdScreeningClinical featuresValidation cohortElevated lipoproteinRisk inspectionARICLp(aReal-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study
Oikonomou E, Aminorroaya A, Dhingra L, Partridge C, Velazquez E, Desai N, Krumholz H, Miller E, Khera R. Real-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study. European Heart Journal - Digital Health 2024, 5: 303-313. PMID: 38774380, PMCID: PMC11104476, DOI: 10.1093/ehjdh/ztae023.Peer-Reviewed Original ResearchRisk of acute myocardial infarctionAssociated with lower oddsHospital health systemCoronary artery diseaseCardiac testingRisk of adverse outcomesUK BiobankHealth systemProvider-drivenLower oddsAssociated with better outcomesAcute myocardial infarctionBlack raceStable chest painFemale sexReal world evaluationDiabetes historyMulticohort studyFunction testsSuspected coronary artery diseaseYounger ageRisk profileAdverse outcomesMultinational cohortPost hoc analysisA WEARABLE-ADAPTED ARTIFICIAL INTELLIGENCE ALGORITHM FOR HEART FAILURE PREDICTION FROM SINGLE-LEAD ELECTROCARDIOGRAMS IN A LARGE NATIONWIDE COHORT STUDY
Dhingra L, Aminorroaya A, Oikonomou E, Sangha V, Khunte A, Khera R. A WEARABLE-ADAPTED ARTIFICIAL INTELLIGENCE ALGORITHM FOR HEART FAILURE PREDICTION FROM SINGLE-LEAD ELECTROCARDIOGRAMS IN A LARGE NATIONWIDE COHORT STUDY. Journal Of The American College Of Cardiology 2024, 83: 2341. DOI: 10.1016/s0735-1097(24)04331-6.Peer-Reviewed Original ResearchCOMPARATIVE CARDIOVASCULAR EFFECTIVENESS OF ANTI-HYPERGLYCEMIC AGENTS INITIATED AS SECOND-LINE THERAPY IN TYPE 2 DIABETES: A LARGE-SCALE, MULTINATIONAL, FEDERATED TARGET TRIAL EMULATION IN THE LEGEND-T2DM STUDY
Khera R, Aminorroaya A, Dhingra L, Bu F, Camargos A, Falconer T, Zhou J, Dorr D, French T, Lau W, Lu Y, Blacketer C, Reyes C, Minty E, Li K, Man K, Ostropolets A, Nishimura A, Matheny M, Yang J, Ryan P, Y.F. W, Krumholz H, Hripcsak G, Suchard M. COMPARATIVE CARDIOVASCULAR EFFECTIVENESS OF ANTI-HYPERGLYCEMIC AGENTS INITIATED AS SECOND-LINE THERAPY IN TYPE 2 DIABETES: A LARGE-SCALE, MULTINATIONAL, FEDERATED TARGET TRIAL EMULATION IN THE LEGEND-T2DM STUDY. Journal Of The American College Of Cardiology 2024, 83: 1977. DOI: 10.1016/s0735-1097(24)03967-6.Peer-Reviewed Original ResearchTRENDS IN KNOWLEDGE OF RISK FACTOR TARGETS AMONG PATIENTS WITH DIABETES MELLITUS IN THE UNITED STATES: A NATIONALLY REPRESENTATIVE STUDY
Bansal B, Aminorroaya A, Dhingra L, Oikonomou E, Khera R. TRENDS IN KNOWLEDGE OF RISK FACTOR TARGETS AMONG PATIENTS WITH DIABETES MELLITUS IN THE UNITED STATES: A NATIONALLY REPRESENTATIVE STUDY. Journal Of The American College Of Cardiology 2024, 83: 1882. DOI: 10.1016/s0735-1097(24)03872-5.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News & Links
News
- November 05, 2024
Yale Researchers at American Heart Association Scientific Session 2024
- August 26, 2024
Which Diabetes Meds Are Best for Reducing Heart Attack and Stroke Risk?
- June 27, 2024
What to Know about Lipoprotein(a)
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions